ClinicalTrials.gg
Enrolling by invitationNCT05159739Updated Nov 13, 2026

Genetic Susceptibility to Periprosthetic Joint Infections

An observational study in Total Joint Arthroplasty and Periprosthetic Joint Infections, sponsored by University of Utah. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University of Utah · Observational

How we know

Updated Nov 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Planned enrollment
36th of 50
150 · median 560
Started
2018
with 4 others
Observational
50 of 87
23 open now
Primary completion
2029-03
later than 27 of 45 live
Registered
55th of 87
by date

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 36th largest by planned enrollment of the 50 observational ones that give a count, is one of 5 that started in 2018, is one of 50 observational ones, reaches primary completion later than 27 of the 45 other live ones, and was the 55th registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

The investigators primary objective is to identify genetic factors that may increase the risk of patients developing a periprosthetic joint infections (PJI) following total joint arthroplasty (TJA). The investigators hope that by identifying genetic predispositions we will be able to provide patient specific care pathways to prevent or minimize the risk for PJI.

Read the detailed description

Surgical site infections (SSI), and more specifically periprosthetic joint infections (PJI), have plagued the orthopaedic surgeon since the introduction of total joint arthroplasty (TJA) procedures of the hip or knee in the mid twentieth century. It is estimated that the economic burden of PJI in the United States will approach 1.62 billion USD by 2020. Though methods of infection control have improved, the rate of PJI appears to have plateaued in the last several decades. Early rates of PJI in the first two decades of THA have been reported between 1 - 9%. Since the 1980's studies have reported rates between 1% - 3%. It has been suggested that as orthopaedic surgeons, doctors should not be satisfied with deep infection rates greater than 1%. Therefore, more must be done in order to prevent, or diminish the frequency, of PJI and its devastating effects on this patient population.

In hopes of allowing for early targeted prevention in potentially high-risk patients, risk calculators have been developed to identify patients at greater risk for developing infection following TJA. However, some investigators suggest that these scoring systems may not be ready for primetime use. Thus, further research is needed to improve the ability to accurately identify individuals at high risk for infection. Unfortunately, the ability to perform large scale longitudinal cohort studies needed to create and test these risk calculators isn't feasible. Thus, other methods of early identification are needed.

Genetic susceptibility testing for identifying patients at risk for disease is becoming more popular and may be a means by which patients at high-risk for PJI can be identified. A recent dermatological study on genetic risk factors for infection suggest that host attributes may play a role in the ability of the individual to be infected. When evaluating the risk of subsequent different site infection in patients with multiple TJA's, investigators suggest that some patients may be at greater risk for infection due to possible subclinical immune deficiencies. In 2013, one investigator reported familial susceptibility to surgical site infections (SSI), including but not isolated to PJI, through a large population based study. Further, a recent publication from this investigating institution demonstrated familial clustering in patients who suffered a PJI, showing an increased risk of PJI following TJA in relatives of patients who have experienced PJI. These families demonstrated infection rates of 9 - 17%. After performing a systematic review on the genetic susceptibility to PJI, the investigators concluded that though evidence exists supporting a genetic role in PJI, no definitive conclusions can be made given the relatively small amount of data available in the existing literature. The investigators further emphasize the need for prospective studies to validate previous findings and the relationship between genetic factors and PJI.

Given the evidence in the literature, the investigators hypothesize that a large familial study will provide greater evidence of a genetic susceptibility. The results of this study could validate previous research with smaller sample sizes and allow for early identification of high-risk patients via genetic susceptibility testing.

03

Conditions studied

  • Total Joint Arthroplasty
  • Periprosthetic Joint Infections

Keywords

  • total joint arthroplasty
  • periprosthetic joint infections
  • genetic susceptibility
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Family members (affected and unaffected) with an increased incidence of TJI with PJI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Families/pedigrees which demonstrate a high-risk for PJI
  • Unaffected family members, up to 3rd degree

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Total Joint Arthroplasty (TJA)

    Recruitment of families with an increased incidence of TJI with PJI.

    Genetic: Blood Draw or Saliva/Cheek Cell Sample:

Interventions

  • GeneticBlood Draw or Saliva/Cheek Cell Sample:

    Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.

    Also known as: Genetic sample

06

What researchers measure

Primary outcomes

  1. Genotyping

    Samples will undergo genetic testing to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.

    Time frame: DNA extraction and analysis will be performed immediately after collection of blood draw or saliva/cheek cell sample by a certified core lab

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for Mar 2029, 132 months after the start.

Of 80 non-industry observational studies under Genetic Predisposition to Disease, half reached primary completion within 96 months of starting (the median), counting those still running; a quarter within 52. This study's planned 132 months is above that.

Counting every sponsor, half of 82 studies reached it within 96 months; a quarter within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Mar 2028 → Mar 2029 and completion Mar 2028 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2021
First posted
Dec 16, 2021
StartActual
Mar 7, 2018
Primary completionEst.
Mar 2029was Mar 2028
CompletionEst.
Mar 2029was Mar 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2028→Mar 2029
Nov 13, 2026
Study completion
Mar 2028→Mar 2029
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Mar 2028→Mar 2029
    Study completion Mar 2028→Mar 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05159739
Lead sponsor
University of Utah
Responsible party
Jeremy Gililland (Principle Investigator, University of Utah) — Principal investigator
First posted
Dec 16, 2021
Start date
Mar 7, 2018
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Jeremy Gililland, M.D.
principal investigator · University of Utah

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion